CGP 49823

Drug Profile

CGP 49823

Latest Information Update: 28 Sep 2000

Price : $50

At a glance

  • Originator Novartis
  • Class Analgesics; Antidepressants; Anxiolytics
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anxiety disorders; Major depressive disorder

Most Recent Events

  • 28 Sep 2000 No-Development-Reported for Depression in Switzerland (Unknown route)
  • 28 Sep 2000 No-Development-Reported for Anxiety disorders in Switzerland (Unknown route)
  • 17 Jun 1997 Phase-II clinical trials for Anxiety disorders in Switzerland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top